Latest Developments on 
Asia’s Biomanufacturing Facilities


The  biologics industry in  Asia-Pacific is  estimated to  be the  fastest growing market in  the world.  For instance,  Asia-Pacific alone  accounts for  almost  30% of the  global biosimilars  market. Low manufacturing costs and  presence of high-skilled workers are some crucial factors that have resulted in Asia-Pacific being seen as a lucrative destination for biologics development. It is estimated that around 50% of the world’s new biomanufacturing facilities are being built in Asia by  both, regional and international companies.

In this  e-book series,  we bring  you key  developments on  Asia’s biomanufacturing facilities. Facilities covered include:
•AbbVie in Singapore
•Aurobindo Pharma in India
•Boehringer Ingelheim in China
•Lonza in Singapore
•Pfizer in China
•Samsung Biologics in Korea
•Stelis Biopharma in India
•Siam Bioscience and CIMAB in Thailand

This eBook is compiled in conjunction with 5th Annual Biologics Manufacturing Asia 2018. For more details, download the program here.

asia biomanufacturing facilities

Get your copy today!

Full Name*

Job Title*

Company*

Mainline of Business

Country

Email*

Telephone*

How did you hear about us?

download_button_final_programme_biologics_manufacturing_asia
register-now-button
sponsorship prospectus button

2018 Event Highlights

GOLD SPONSORS

GOLD SPONSORS

Silver Sponsor

Silver Sponsor

Associate Sponsor

Associate Sponsor

EXHIBITORS

EXHIBITORS

Media Partners

Media Partners

Co-Located With

biologistics_world_asia_event_2019_logo

Awards Nomination

Awards Nomination